Elanco Animal Health Incorporated Unrecognized Tax Benefits, Increase Resulting from Acquisition
Elanco Animal Health Incorporated (ELAN) reported Unrecognized Tax Benefits, Increase Resulting from Acquisition of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-25.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition · last filed 2025-02-25
- Elanco Animal Health Incorporated unrecognized tax benefits, increase resulting from acquisition for fiscal 2024 was $0.00.
- Elanco Animal Health Incorporated unrecognized tax benefits, increase resulting from acquisition for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Elanco Animal Health Incorporated unrecognized tax benefits, increase resulting from acquisition for fiscal 2022 was $7.00M, a 75.00% increase from fiscal 2021.
- Elanco Animal Health Incorporated unrecognized tax benefits, increase resulting from acquisition for fiscal 2021 was $4.00M.
| Period end | Unrecognized Tax Benefits, Increase Resulting from Acquisition 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-25 |
| 2023-12-31 | $0.00 10-K · filed 2025-02-25 |
| 2022-12-31 | $7.00M 10-K · filed 2025-02-25 |
| 2021-12-31 | $4.00M 10-K · filed 2024-02-26 |
| 2020-12-31 | $0.00 10-K · filed 2023-03-01 |
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |